- Home
- TRVI vs BMEA Comparison
TRVI vs BMEA Comparison
Compare TRVI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- BMEA
- Stock Information
- Founded
- TRVI 2011
- BMEA 2017
- Country
- TRVI United States
- BMEA United States
- Employees
- TRVI N/A
- BMEA N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- BMEA Health Care
- Exchange
- TRVI Nasdaq
- BMEA Nasdaq
- Market Cap
- TRVI 211.4M
- BMEA 209.8M
- IPO Year
- TRVI 2019
- BMEA 2021
- Fundamental
- Price
- TRVI $4.51
- BMEA $4.23
- Analyst Decision
- TRVI Strong Buy
- BMEA Buy
- Analyst Count
- TRVI 8
- BMEA 13
- Target Price
- TRVI $9.31
- BMEA $37.25
- AVG Volume (30 Days)
- TRVI 4.0M
- BMEA 827.4K
- Earning Date
- TRVI 11-06-2024
- BMEA 10-29-2024
- Dividend Yield
- TRVI N/A
- BMEA N/A
- EPS Growth
- TRVI N/A
- BMEA N/A
- EPS
- TRVI N/A
- BMEA N/A
- Revenue
- TRVI N/A
- BMEA N/A
- Revenue This Year
- TRVI N/A
- BMEA N/A
- Revenue Next Year
- TRVI N/A
- BMEA N/A
- P/E Ratio
- TRVI N/A
- BMEA N/A
- Revenue Growth
- TRVI N/A
- BMEA N/A
- 52 Week Low
- TRVI $1.26
- BMEA $3.61
- 52 Week High
- TRVI $4.60
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- TRVI 75.02
- BMEA 23.76
- Support Level
- TRVI $2.36
- BMEA $5.55
- Resistance Level
- TRVI $4.60
- BMEA $6.06
- Average True Range (ATR)
- TRVI 0.33
- BMEA 0.49
- MACD
- TRVI 0.21
- BMEA -0.08
- Stochastic Oscillator
- TRVI 92.46
- BMEA 0.50
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.